This study also reported that pharmacological inhibition of MPO through treatment with AZM198, an MPO inhibitor, could repress NASH progression and liver fibrosis induced by feeding a high-fat, high-cholesterol diet (HFHCD) (91). Here, MPO is linked to metabolic dysfunction-associated steatohepatitis.